What smart money is saying about Madrigal Pharmaceuticals
2 funds in our archive have pitched Madrigal Pharmaceuticals — most recently Artisan US Small Cap Growth Strategy in September 2025.
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Fund coverage · 2 theses
- Artisan US Small Cap Growth StrategySeptember 2025
Madrigal Pharmaceuticals is a biotech company focused on treating metabolic dysfunction-associated steatohepatitis (MASH) with its FDA-approved drug Resdiffra™.
Read the full thesis - Artisan US Small Cap Growth StrategyJune 2025
Madrigal Pharmaceuticals is a leading biotechnology company specializing in the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with its FDA-approved drug Resdifra™, which effectively targets liver fibrosis.
Read the full thesis
Read every full thesis on Madrigal Pharmaceuticals
Unlock all 2 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→